drugset / Trial / NCT05918640
Lurbinectedin in FET-Fused Tumors
Phase 1/2
Recruiting
63 enrolled
Children's Hospital of Philadelphia
Jazz Pharmaceuticals · collabStand Up To Cancer · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to find out if a drug called lurbinectedin (the "study drug") is safe and effective at treating people with recurrent or relapsed solid tumors, including Ewing sarcoma.
Timeline
- Start
- 2023-07-27
- Primary completion
- 2027-07-30
- Completion
- 2028-07-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lurbinectedin | Other / unclassified | — | — |